MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: BioPharmaceutical Drug Discovery & Development (Miscellaneous)
Parabilis Medicines (PBLS), formerly, Fog Pharmaceuticals, Inc. (FogPharma)
Finance & Acquisitions: FogPharma
Parents
Parabilis Medicines (PBLS), formerly, Fog Pharmaceuticals, Inc. (FogPharma)
Children
2024: FogPharma bags $145M, adds Alexis Borisy to the board
2026: Parabilis sets a record with a $670M biotech IPO
2026: The company is supported by a strong life science venture capital syndicate that includes ARCH Venture Partners, Cormorant, FMR (Fidelity), GV (Google), Milky Way Investments, Nextech VII Oncology, RA Capital, and venBio.
2026: Will receive a $50 million upfront payment from collaborator Regeneron Pharmaceuticals, Inc. (REGN), which will also purchase $75 million in shares in a concurrent private placement transaction, as previously mentioned.
Jumps
Key People: FogPharma
Organization & Developments: FogPharma